Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
| Market Cap | 323.90M+122.0% |
| Revenue (ttm) | 0 |
| Net Income | -90.82M-33.1% |
| EPS | -3.31+3.8% |
| Shares Out | 48.89M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,661.807 |
| Open | 6.89 |
| Previous Close | 7.00 |
| Day's Range | 6.58 - 6.92 |
| 52-Week Range | 2.71 - 14.53 |
| Beta | 2.41 |
| Analysts | Buy |
| Price Target | 37.50(+466.04%) |
| Earnings Date | Nov 11, 2026 |
Artiva Biotherapeutics, Inc. has a live Insider Score.
Scored on 9 qualifying trades from 1 insider in the last 90 days.
About ARTV
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ARTV stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ARTV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ARTV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ARTV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ARTV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ARTV from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ARTV
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $7.91M |
| IWMiShares Russell 2000 ETF | $3.42M |
| VXFVanguard Extended Market ETF | $3.04M |
| SURISimplify Propel Opportunities ETF | $709.49K |
| IWCiShares Micro-Cap ETF | $422.69K |
| IWOiShares Russell 2000 Growth ETF | $350.96K |
Estimated from each fund’s disclosed top holdings × AUM
ARTV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ARTV’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score